<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>NTM Antimicrobial Guide</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Orbitron:wght@400;600&family=Press+Start+2P&display=swap" rel="stylesheet">
    <style>
        :root {
            --neon-pink: #ff2d95;
            --neon-blue: #2de2e6;
            --neon-purple: #9d4edd;
            --dark-bg: #0b1026;
        }

        body {
            font-family: 'Orbitron', sans-serif;
            margin: 0;
            padding: 0;
            min-height: 100vh;
            background: var(--dark-bg);
            color: #ffffff;
            display: flex;
            flex-direction: column;
            align-items: center;
            justify-content: center;
            position: relative;
            overflow-x: hidden;
        }

        body::before {
            content: '';
            position: fixed;
            top: 0;
            left: 0;
            width: 100%;
            height: 100%;
            background: 
                linear-gradient(transparent 0%, rgba(11, 16, 38, 0.5) 95%),
                linear-gradient(90deg, rgba(255, 45, 149, 0.1) 0%, transparent 100%);
            z-index: -2;
        }

        body::after {
            content: '';
            position: fixed;
            top: 0;
            left: 0;
            width: 200%;
            height: 200%;
            background: 
                linear-gradient(transparent 65%, rgba(11, 16, 38, 0.8) 75%, var(--dark-bg) 85%),
                repeating-linear-gradient(
                    90deg,
                    transparent 0%,
                    transparent 1%,
                    rgba(255, 45, 149, 0.1) 1.5%,
                    transparent 2%
                ),
                repeating-linear-gradient(
                    180deg,
                    transparent 0%,
                    transparent 3%,
                    rgba(45, 226, 230, 0.1) 3.5%,
                    transparent 4%
                );
            transform: perspective(100vh) rotateX(60deg) translateY(-50%) translateZ(0);
            transform-origin: 50% 0;
            z-index: -1;
            animation: grid-move 15s linear infinite;
        }

        @keyframes grid-move {
            0% {
                transform: perspective(100vh) rotateX(60deg) translateY(-50%) translateZ(0);
            }
            100% {
                transform: perspective(100vh) rotateX(60deg) translateY(0%) translateZ(0);
            }
        }

        .container {
            max-width: 1200px;
            padding: 2rem;
            width: 95%;
            z-index: 1;
            background: rgba(11, 16, 38, 0.7);
            border-radius: 8px;
            border: 2px solid var(--neon-purple);
            box-shadow: 
                0 0 10px var(--neon-purple),
                inset 0 0 10px var(--neon-purple);
        }

        h1 {
            font-family: 'Press Start 2P', cursive;
            font-size: 1.5rem;
            font-weight: 400;
            margin-bottom: 2rem;
            text-align: center;
            color: var(--neon-pink);
            text-shadow: 
                0 0 5px var(--neon-pink),
                0 0 10px var(--neon-pink);
            line-height: 1.5;
        }

        .back-link {
            display: inline-block;
            margin-bottom: 2rem;
            color: var(--neon-blue);
            text-decoration: none;
            font-family: 'Press Start 2P', cursive;
            font-size: 0.8rem;
            text-shadow: 0 0 5px var(--neon-blue);
            transition: all 0.3s ease;
        }

        .back-link:hover {
            color: #fff;
            text-shadow: 
                0 0 5px var(--neon-blue),
                0 0 10px var(--neon-blue),
                0 0 20px var(--neon-blue);
        }

        table {
            width: 100%;
            border-collapse: separate;
            border-spacing: 0;
            margin: 1rem 0;
            background: rgba(11, 16, 38, 0.8);
            border-radius: 8px;
            overflow: hidden;
        }

        th, td {
            padding: 1rem;
            text-align: left;
            border: 1px solid var(--neon-purple);
        }

        th {
            background: rgba(157, 78, 221, 0.2);
            color: var(--neon-blue);
            font-family: 'Press Start 2P', cursive;
            font-size: 0.7rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            text-shadow: 0 0 5px var(--neon-blue);
        }

        td {
            font-size: 0.9rem;
            line-height: 1.4;
        }

        tr:hover td {
            background: rgba(157, 78, 221, 0.1);
        }

        @media (max-width: 768px) {
            .container {
                padding: 1rem;
                width: 90%;
            }

            h1 {
                font-size: 1rem;
            }

            th, td {
                padding: 0.5rem;
                font-size: 0.8rem;
            }

            table {
                display: block;
                overflow-x: auto;
                white-space: nowrap;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <a href="index.html" class="back-link">← Back to Home</a>
        <h1>Table 4. Summary of Antimicrobial Dosing, Target Therapeutic Drug Monitoring Values, Adverse Effects, Drug Interactions, and Respective Management</h1>
        <table>
            <thead>
                <tr>
                    <th>Antimicrobial</th>
                    <th>Dosing</th>
                    <th>Therapeutic Drug Monitoring Targets</th>
                    <th>Adverse Effects and Drug Interactions</th>
                    <th>Suggested Monitoring and Management</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Azithromycin</td>
                    <td>250–500 mg PO/IV daily; 500 mg 3x weekly</td>
                    <td>Cmax: 0.2–0.7 µg/mL</td>
                    <td>GI intolerance, reversible hearing loss, tinnitus, QTc prolongation, hypersensitivity, transient transaminitis</td>
                    <td>Clinical evaluation, LFTs at baseline and every 1–2 months, ECG if QTc-prolonging agents used. Hold for significant adverse events.</td>
                </tr>
                <tr>
                    <td>Clarithromycin</td>
                    <td>500 mg PO twice daily</td>
                    <td>Cmax: 2–5 µg/mL</td>
                    <td>GI intolerance, reversible hearing loss, tinnitus, QTc prolongation, CYP3A4 inhibition, drug interactions, hepatotoxicity (rare)</td>
                    <td>Clinical evaluation, LFTs at baseline and every 1–2 months, ECG if combined with QTc-prolonging agents. Adjust medications accordingly.</td>
                </tr>
                <tr>
                    <td>Rifampin</td>
                    <td>10 mg/kg PO daily (max 600 mg)</td>
                    <td>Cmax: 8–24 µg/mL</td>
                    <td>Hepatotoxicity, drug interactions (CYP inducer), thrombocytopenia, GI upset, orange discoloration of secretions</td>
                    <td>Clinical evaluation, LFTs every 1–2 months. Monitor for drug interactions.</td>
                </tr>
                <tr>
                    <td>Rifabutin</td>
                    <td>300 mg PO daily (dose adjust with interactions)</td>
                    <td>Cmax: 0.4–0.6 µg/mL</td>
                    <td>Neutropenia, uveitis, hepatotoxicity, drug interactions, orange discoloration of secretions</td>
                    <td>Clinical evaluation, CBC and LFTs every 1–2 months. Dose adjust with interacting agents.</td>
                </tr>
                <tr>
                    <td>Ethambutol</td>
                    <td>15–25 mg/kg PO daily</td>
                    <td>Cmax: 2–6 µg/mL</td>
                    <td>Optic neuritis, rash, arthralgia, hepatotoxicity</td>
                    <td>Clinical evaluation, baseline and monthly visual acuity and color vision testing, LFTs every 1–2 months.</td>
                </tr>
                <tr>
                    <td>Amikacin (IV)</td>
                    <td>15–20 mg/kg IV daily or 3x weekly</td>
                    <td>Peak: 35–45 µg/mL; Trough: &lt;5 µg/mL</td>
                    <td>Nephrotoxicity, ototoxicity, vestibular toxicity</td>
                    <td>Clinical evaluation, baseline and periodic audiometry, renal function, monitor serum levels.</td>
                </tr>
                <tr>
                    <td>Amikacin (Inhaled)</td>
                    <td>590 mg nebulized daily</td>
                    <td>Not applicable</td>
                    <td>Ototoxicity, bronchospasm, oral candidiasis, dysphonia, hemoptysis</td>
                    <td>Baseline spirometry, monitor oral cavity discomfort, rechallenge after 1-week holiday if tolerated.</td>
                </tr>
                <tr>
                    <td>Streptomycin</td>
                    <td>10–15 mg/kg IV daily or 3x weekly</td>
                    <td>Peak: 20–30 µg/mL; Trough: &lt;2 µg/mL</td>
                    <td>Nephrotoxicity, ototoxicity, vestibular toxicity</td>
                    <td>Baseline audiometry, renal function, monitor peaks/troughs, adjust dosing based on renal function.</td>
                </tr>
                <tr>
                    <td>Moxifloxacin</td>
                    <td>400 mg PO/IV daily</td>
                    <td>Cmax: 3–5 µg/mL</td>
                    <td>QTc prolongation, hepatitis, nausea, vomiting, tendinitis, aortic dissection (rare)</td>
                    <td>Clinical evaluation, ECG at baseline and regularly, Cr and LFTs every 1–2 months, electrolyte management.</td>
                </tr>
                <tr>
                    <td>Bedaquiline</td>
                    <td>400 mg PO daily for 14 days, then 200 mg three times weekly</td>
                    <td>QTc prolongation monitoring</td>
                    <td>QTc prolongation, hepatitis, elevated amylase, nausea, rash, joint pain</td>
                    <td>Clinical evaluation, ECG baseline and periodically, LFTs every 1–2 months, electrolyte management.</td>
                </tr>
                <tr>
                    <td>Linezolid</td>
                    <td>600 mg PO/IV twice daily</td>
                    <td>Cmax: 12–26 µg/mL</td>
                    <td>Myelosuppression, peripheral/optic neuropathy, serotonin syndrome</td>
                    <td>Clinical evaluation, CBC weekly, monitor for neuropathy, monitor for serotonin syndrome if combined with serotonergic agents.</td>
                </tr>
                <tr>
                    <td>Clofazimine</td>
                    <td>100 mg PO daily</td>
                    <td>Not established</td>
                    <td>Skin discoloration, GI intolerance, QTc prolongation, hepatotoxicity</td>
                    <td>Clinical evaluation, ECG baseline and periodically, LFTs every 1–2 months.</td>
                </tr>
                <tr>
                    <td>Trimethoprim-Sulfamethoxazole (TMP-SMX)</td>
                    <td>800/160 mg PO/IV twice daily</td>
                    <td>Adjust based on renal function</td>
                    <td>GI intolerance, cytopenias, hyperkalemia, renal injury, hypersensitivity, hepatitis</td>
                    <td>Clinical evaluation, Cr, electrolytes, LFTs, and CBC monthly. Discontinue for severe adverse events.</td>
                </tr>
            </tbody>
        </table>
    </div>
</body>
</html>